These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 16444969)

  • 41. Successful salvage therapy of irinotecan for relapsed Hodgkin's lymphoma.
    Urushihata K; Koizumi T; Kaneki T; Yamaguchi S; Fujimoto K; Kubo K
    Intern Med; 2002 Aug; 41(8):648-50. PubMed ID: 12211535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide.
    Tempescul A; Ianotto JC; Bagacean C; Salaun PY; Bocsan C; Zdrenghea M
    Int J Hematol; 2016 Sep; 104(3):400-2. PubMed ID: 27233512
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
    Okahashi N; Uchihara M; Hoshino E
    Rinsho Ketsueki; 2020; 61(10):1508-1510. PubMed ID: 33162449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Case Report: Ocular Manifestation of Mantle Cell Lymphoma.
    Hafeez S; Mancini A; Mega J; Greenberg PB; Siegel C; Hunter A
    Optom Vis Sci; 2022 Feb; 99(2):186-189. PubMed ID: 34889856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Thalidomide combined with interferon in relapsed or refractory mantle cell lymphoma: two cases report and literatures review].
    Zhao HF; Wei XD; Yin QS
    Zhonghua Xue Ye Xue Za Zhi; 2012 Sep; 33(9):776-7. PubMed ID: 23336241
    [No Abstract]   [Full Text] [Related]  

  • 46. Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis.
    Khurana A; Dalland JC; Young JR; Inwards DJ; Paludo J
    Am J Hematol; 2021 Aug; 96(8):E298-E301. PubMed ID: 33984157
    [No Abstract]   [Full Text] [Related]  

  • 47. Prognostic impact of monocyte count at presentation in mantle cell lymphoma.
    George A; Prince HM; Szer J; Wolf M; Januszewicz EH; Seymour JF; Ritchie DS
    Br J Haematol; 2014 Mar; 164(6):890-3. PubMed ID: 24266507
    [No Abstract]   [Full Text] [Related]  

  • 48. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Successful salvage therapy of continuous low-dose irinotecan for a patient with relapsed and refractory diffuse large B-cell lymphoma].
    Masaki Y; Sawaki T; Shimoyama K; Karasawa H; Kawanami T; Fukushima T; Kawabata H; Ogawa N; Wano Y; Sugai S; Hirose Y; Umehara H
    Rinsho Ketsueki; 2005 Sep; 46(9):1074-7. PubMed ID: 16440768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Successful treatment of chemotherapy-resistant adult T cell leukemia/lymphoma by irinotecan hydrochloride (CPT-11)].
    Makino T; Nakahara K; Takatsuka Y; Shimotakahara S; Utsunomiya A; Hanada S; Tokunaga M; Arima T
    Rinsho Ketsueki; 1994 Jan; 35(1):42-8. PubMed ID: 8139101
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
    Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
    J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Successful treatment of refractory mantle cell lymphoma with irinotecan].
    Hara S; Yokote T; Akioka T; Oka S; Yamano T; Tsuji M; Hanafusa T
    Rinsho Ketsueki; 2005 May; 46(5):358-62. PubMed ID: 16444969
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.